What this study adds:
treatment of diabetes were not the most highly used drugs in Australia, their use increased during the study period, from 42.64 to 48.61 DDD/1,000/day. Anti-diabetic drugs were the most frequently dispensed class of drugs in 
Conclusion
The use of drugs to treat diabetes does not reflect the usage patterns found in Australia. Effective drug use reviews are required to ensure impartial access in middle-and lowincome countries.
Background
Once a disease of developed countries, type 2 diabetes mellitus (T2DM) has become widespread worldwide. For people with T2DM, achievement of therapeutic outcomes demands the rational and quality use of medicine.
Aims
The primary aim of this study was to examine the prevalence of diabetes and prescribing patterns of antidiabetic medications in Australia and Malaysia.
Methods
The most recent, publicly available, statistical reports (2004) (2005) (2006) (2007) (2008) on the use of medicines published in Australia and in Malaysia were evaluated. Defined daily doses (DDDs/1,000 population/day) were derived from the reports and used to rank and compare individual drug use.
Results
There was an increasing trend in the prevalence of diabetes in Australia, although there is a greater predicted increase in prevalence for Malaysia. While drugs used for the
Background
Diabetes mellitus is a chronic, progressive disorder that affects millions of people worldwide. 1 Once a disease of developed countries, type 2 diabetes mellitus (T2DM) is now in every country. 2 Global estimates published in 2010
reported the world prevalence as 6.4 per cent, affecting 285 million adults (aged 20-79 years); the incidence is predicted to rise to 7.7 per cent and 439 million by 2030. 3 The predicted increase in patients with diabetes is nearly twice the annual growth of the total world adult population. Dispensing trends reflect the use of drugs and therefore the treatment of medical conditions. 13 The primary aim of this descriptive study was to examine the prevalence of diabetes and prescribing patterns of anti-diabetic medications in Australia and Malaysia, to evaluate prescribing trends and their concordance with national and international treatment guidelines. This comparison was made between a developed country with adequate health resources and an increasing prevalence of diabetes (Australia), and a middleincome developing country with a high prevalence of diabetes (Malaysia). The underpinning research question was: How does the use of drugs to treat diabetes differ between Australia and Malaysia? The findings potentially serve as a means of improving the quality use of medicine, enhancing therapeutic outcomes, and indicating over-or under-consumption of medicines in both countries.
Method
Assessing the prevalence of diabetes in Australia and Malaysia The prevalence of diabetes in this paper is presented using estimates reported by Shaw et al., 3 where the authors derived prevalence estimates for Australia from the Australian Diabetes, Obesity and Lifestyle Study, 14 and the National Diabetes Service Scheme, Diabetes Australia. 15 The prevalence of diabetes in Malaysia is based on figures published in the National Health and Morbidity Survey (NHMS) reports. 5, 7 NHMS is a nationwide survey of selfreported data that include medicine use, dietary habits, various disease states, and demographics, which were first published in 1986 and is now published every 10 years.
5,7
Although we focused on both types (type 1 and 2) of diabetes in this study, about 90 per cent of all cases of diabetes in both countries are T2DM.
3
Assessing diabetes-related medicines use Publicly available Australian and Malaysian reports containing statistics on medicine use for each year from 2004 to 2008 (inclusive) were used; the focus for this paper was anti-diabetic drugs. 16, 17 The published reports from both countries adopted the same unit (DDD/1,000 population/day) to describe medicine usage which facilitated comparison between the two countries. Dispensing databases are compiled from claims data and essentially such data are designed for administrative purposes; however, the large size of such databases makes them suitable for drug utilisation studies despite their lack of clinical information. 
Medicines use data, Malaysia
The Ministry of Health in Malaysia publishes statistics on medicines using retrospective data derived from the Ministry of Health (public institutions), as well as from private hospitals, university and armed forces, (private) GP prescribing, and (private) pharmacy dispensing. 16 The medicines provided through public hospitals or clinics are dispensed free of charge to Malaysian citizens and reports are therefore restricted to "prescription" medicines, 16 while prescription medicines dispensed in community pharmacies are paid for in full by the patient. The first Malaysian Statistics on Medicine (MSM) report published in 2013 contains data from 2008. 16 The major anti-diabetic drug classes included for comparison were insulin and analogues, biguanides, sulfonylureas, alpha glucosidase, thiazolidinediones, and dipeptidyl peptidase 4 inhibitors. Descriptive analyses presented in the tables and figures in this paper were carried out using Microsoft Excel (Microsoft Corp., Palo Alto, CA). Descriptive statistics were used to analyse frequency, percentage, and mean.
Results

Diabetes prevalence
The population characteristics of Malaysia (a developing country) and Australia (a developed country) for the period of this study were similar. 21, 22 There was an increasing trend in the percentage prevalence of diabetes in both countries; however, it was 1.5 times higher in Malaysia (10.9) than Australia (7.2). 
Discussion
There were similar trends of increasing diabetes prevalence between the two countries but marked differences in the use of anti-diabetic drugs. Based on global estimates, the prevalence of diabetes in Malaysia is significantly higher than Australia, a difference that is predicted to continue to widen by 2030. 3 The increasing prevalence among adults aged ≥18 years in Malaysia has been reported elsewhere; 5, 7, 23 we observed that the prevalence was steeper in Malaysia than Australia. The situation in Malaysia is alarming and as the prevalence of diabetes is expected to increase, the number of patients with diabetes-diagnosed and undiagnosed, treated, and untreated-is expected to rise proportionately. Previous studies in Malaysia using NHMS III data reported that diabetes was most prevalent among Malaysians of Indian origin (37.9 per cent) and among people aged between 45-75 years of age (>20 per cent); 5,7 however, it was comparable between genders and geographical locations. 7 The incidence of diabetes in Australia was also reported to increase at around 45 years of age and by 2008, was highest among patients aged 75 years and over. 10 However, a few years later (2011-12), the age group with the highest incidence of diabetes had decreased to 65-74 years.
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Regarding gender, just more than half (52 per cent) of all diabetic cases (T1DM and T2DM) in Australia occurred among women in 1995, 9 while many years later (2011-12), more men in Australia reported having diabetes (4.3 per cent) than women (3.6 per cent).
Despite the high prevalence of diabetes among people living in Malaysia, the use of drugs to treat diabetes was not as high as expected due to high prevalence of diabetes. It has also been reported that less than one-quarter of patients achieve their target HbA1c level (<7 per cent), 24 which suggests that there may be a large number of people with untreated diabetes in Malaysia or diabetics who do not take appropriate medication. 5 Perhaps surprisingly, while the 10 most frequently dispensed drugs in Malaysia included those to treat diabetes, 16 in Australia the most frequently dispensed drugs were drugs to treat cardiovascular conditions. 17 Despite the fact that there were no antidiabetic drugs included among the 10 most frequently dispensed drugs in Australia, it is interesting that their use was higher than in Malaysia, at 4.35 DDD/1,000/day, on average.
The two most frequently dispensed drug classes in Malaysia were biguanides and sulfonylureas. In Australia, the most frequently used anti-diabetic drugs were biguanides and insulins. The increased use of metformin in Malaysia indicates (improved) adherence to prescribing guidelines, which recommend metformin as first-line oral medication, particularly for obese individuals. 25, 26 The introduction of the fixed-dose combination of metformin and sulfonylurea may be associated with improved patient compliance and hence, use. 16, 26 In Australia, metformin use followed a similar increasing trend during the study period. Due to the progressive failure of insulin secretion, therapy has to be increased over time. 28, 29 Patients with T2DM who do not achieve optimal glycaemic control with oral antidiabetic drugs (HbA1c <7.0 per cent) may require insulin therapy, and should start insulin therapy as soon as possible if HbA1c >9.0 per cent and blood glucose levels >15mmol/L. 30, 31 The early use of insulin in the treatment of T2DM is not without controversy both in terms of microvascular and macro-vascular complications. 32 However, studies included in the National Institute for Health and Care Excellence (NICE) guidelines suggest that combination treatment with insulin and metformin, or insulin and a sulfonylurea, show significantly lower HbA1ac levels compared to insulin monotherapy. 29 Results from clinical trials have led to international management guidelines emphasising the importance of blood glucose control to reduce vascular complications in people with diabetes. [33] [34] [35] A number of potential barriers to and lower acceptance of insulin use among Malaysian patients have been identified. These include lack of knowledge (e.g., fear of injections, glucose monitoring, patient ignorance, lack of awareness about the importance of diabetes treatment), 5, 16, 36 negative side effects (e.g., insulin-related hypoglycaemia), 16, 36 patients' preference (e.g., oral medication, alternative medicines), 16, 37, 38 and cost of treatment. 36 The affordability or availability of drugs may also be a factor as it has been reported that essential drugs are expensive in Malaysia and are not available in all areas such as the far-eastern region where the logistics of transporting medicines is challenging. 39 Due to the increasing burden of chronic diseases in Malaysia, the Malaysian government has increased the spending on health-related issues; however, undertreatment, under-diagnosis, non-adherence, and the use of traditional medicines may lead to sub-optimal use of antidiabetic agents. We suggest that a crucial step may have been overlooked: robust screening strategies should be conducted in urban and rural areas, to identify patients at risk of, and suffering from, undiagnosed diabetes. To control, delay, or prevent complications associated with diabetes effective prescribing through targeted training and professional development of healthcare professionals, and patient education on appropriate treatment, must be promoted by the authorities responsible for coordinating services, resources, and facilities. 16 It is also possible that only essential and accessible sources were included in the collection of data. It is known that Australian reports may underestimate the use of under-co-payment medicines (i.e., non-subsidised medicines, which are therefore not included in the claims databases) by up to 20 per cent. 17 Finally, this drug utilisation study is based on reports of dispensing data and the drugs may not necessarily have been consumed.
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Conclusion
This comparative study highlights differing prescribing trends between Malaysia and Australia. Although there is an increasing trend in the prevalence of people with diabetes in both countries, the use of drugs to treat diabetes in Malaysia does not reflect the patterns of anti-diabetic drug use in Australia. Insulin is considered to be the most appropriate form of treatment for certain types or stages of diabetes and more research into the low use of insulin in Malaysia is required. It will therefore be necessary to lay a firm foundation for the development of educational interventions, review of treatment guidelines, and education of prescribers and patients to increase the acceptance of insulin therapy. Moreover, effective drug use review to promote rational medicine use should be included in the diabetes management protocol in Malaysia. DDD=Daily defined doses
